Expert Interviews

With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.

Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.

Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.

Treatment with CAR T-cell therapy for LBCL, like liso-cel, can impact QOL based on restrictions made on the label.

The 48-month OS rate for the TRANSFORM plus long-term follow-up study was 61.5% for patients with R/R LBCL.

Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.

Reveals that resistance complexity and heterogeneity were notably lower with dual-targeted treatment.

Experts discuss tailored approaches to neoadjuvant therapy for esophageal and G-junction cancers, emphasizing the importance of multidisciplinary care.

Explore the evolving landscape of cancer treatment strategies, focusing on guideline-based management and the impact of multimodal approaches on patient outcomes.

Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.

Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.

Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.

Demonstrates that longer amivantamab exposure further reduces the emergence of MET and EGFR mutations.

Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.

The experts conclude this program by discussing future biomarker-guided approaches in bladder cancer treatment.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Misako Nagasaka, MD, PhD, summarizes the key takeaways: proactive AE management, CNS vigilance, and strategic sequencing as hallmarks of modern care for EGFR-mutant NSCLC.

Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.

The discussion underscores the role of multidisciplinary coordination in maintaining adherence, quality of life, and long-term therapeutic benefit.

Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.